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With hepatitis B and C, the European region is confront-
ing a devastating epidemic that seemingly has emerged in
silence. The major driver of hepatitis B and C in Europe is
now injecting drug use. Yet it would be a mistake to think
of these diseases as a problem primarily for people who
inject drugs (PWID). They are a problem for governments,
health systems, communities, families and all who care
about the rights and dignity of the most marginalised
members of our society.
The first European Conference on Hepatitis C and
Drug Use, slated for 23-24 October 2014, may well be
seen in retrospect as a landmark event spurring the
emergence of the broad-based movement that is needed
to alter the course of the region’s hepatitis epidemic.
The conference’s international organising partner, the
Correlation Network’s Hepatitis C Initiative, has utilised
financial support from the Drug Prevention and Infor-
mation Programme of the European Union to publish a
journal supplement in conjunction with the conference.
We, the editors of the supplement, are proud to have
had this opportunity to bring together information and
viewpoints about some of the most important issues on
the conference agenda. We trust that the publication
will both inform the current dialogue around key issues
and also find a place as a core resource for the many
additional people who will surely be drawn to this work
in the years to come.
The European Conference on Hepatitis C and Drug
Use takes place at a pivotal time. The first-ever World
Health Assembly resolution on viral hepatitis in 2010
[1] generated momentum in relation to key strategy and
policy issues at the global level, as reflected in the viral
hepatitis strategic framework announced by the World
Health Organization (WHO) in 2012 [2]. In 2013, WHO
followed up by asking Member States to report on exist-
ing national policies and practices in relation to the four
axes of the strategic framework. The resulting Global
Policy Report on the Prevention and Control of Viral
Hepatitis in WHO Member States [3] provides a bench-
mark for measuring progress on a number of critical
issues.
In the spring of 2014, WHO’s hepatitis programme
convened its first-ever “global partners meeting,” and the
resulting “Call to Action to Scale Up Global Hepatitis
Response” captured the major concerns of the many civil
society organisations that attended the meeting [4]. Not
long afterwards, strong civil society engagement helped
to ensure passage of a new World Health Assembly
resolution [5] that obligates governments to take more
concrete measures in response to viral hepatitis. Civil
society again came together to contribute to the first
Global Community Hepatitis Policy Report, released by
the World Hepatitis Alliance on World Hepatitis Day
2014 [6].
The importance of addressing the viral hepatitis preven-
tion and treatment needs of people who inject drugs has
been a strand running through all of these developments.
Indeed, one of the key advocacy victories associated with
the new World Health Assembly resolution is the inclu-
sion of commitments relating to people who inject drugs.
The resolution calls on WHO Member States to “imple-
ment comprehensive hepatitis prevention, diagnosis and
treatment programmes for people who inject drugs.” Foot-
noted text names nine key interventions, including needle
and syringe programmes; opioid substitution therapy and
other drug dependence treatment; and targeted informa-
tion, education and communication for people who inject
drugs and their sexual partners [5].
In short, this is an opportune time to bring PWID
issues to the forefront in discussions about how to rein
in hepatitis B and C in Europe and globally.
The discussions underway in policy, advocacy and
research circles are by necessity very broadly focused.
Viral hepatitis prevention efforts must overcome
immense obstacles associated with low public awareness
and misconceptions about the nature of the threat. The
same factors hinder health systems from identifying a
vast number of infected but currently asymptomatic and
undiagnosed people who might benefit from treatment.
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There is also much to be resolved around fundamental
matters such as uniform disease surveillance standards
and treatment initiation criteria. The hepatitis C treatment
cascade needs to be more clearly conceptualised so that
vital questions can be pursued regarding how to engage,
retain and successfully treat far more people.
PWID issues are not an “add-on” to this already
daunting agenda. They are cross-cutting throughout the
agenda, for the simple reason that people who inject
drugs are commonly the human face of the hepatitis B
and C epidemics in many countries, including a large
number of countries in Europe. Successfully engaging
these individuals in prevention and treatment efforts
means addressing a complex public health threat within
the context of other equally complex threats – such as
addiction, mental illness, financial instability and the
stigmatisation and criminalisation of drug users.
The WHO European region has an estimated 15 million
people living with hepatitis C, of whom an estimated two
million are current drug injectors [7]. At the same time,
only 30% of European countries submitting information to
WHO for the 2013 policy report indicated that they have
comprehensive national viral hepatitis strategies or plans.
Seventy percent told WHO that they have hepatitis pre-
vention policies targeting PWID. With such large gaps in
national leadership, it is no wonder that the overall public
health response to the viral hepatitis epidemic among
PWID appears to be so fragmented.
Yet the lack of a high-profile discourse regarding how to
elaborate the strategies suggested by the WHO framework
should not be interpreted as a lack of interest in hepatitis
and PWID. As the contributions to this supplement sug-
gest, a vast array of people and organisations have been
quietly forging ahead in their own communities and peer
networks. The collective wisdom accruing through these
efforts must be shared more widely, and it must be shared
as quickly as possible – there is absolutely no time to lose.
In this context, the supplement editors hope that the
publication and conference together help usher in a new
era of knowledge-sharing among those who are committed
to preventing and treating hepatitis B and C among people
who inject drugs. We are pleased to note that the supple-
ment presents no less than ten commentaries about
crucial issues in this realm, and we are equally pleased
about the diversity of experiences represented in the
contributions. To illustrate:
• In “No Strategy to Meet the HCV Epidemic,” Olav
Dalgard and Stefan Mauss of the European Association
for the Study of the Liver discuss some of the vast
implications of the changing hepatitis C treatment para-
digm, including the opportunity to raise awareness
about prevention.
• Achim Kautz and colleagues at the European Liver
Patients Association broadly outline key strategic
considerations in relation to improving hepatitis C
screening and treatment for PWID in Europe.
• Chris Ford and Juliet Bressan, United Kingdom-based
physicians with a wealth of knowledge about addiction
services, argue forcefully for the decriminalisation of peo-
ple who use drugs as a strategic element of the hepatitis
C response.
• In “A Treatment Revolution for Those Who Can
Afford It?” Maria Phelan and Catherine Cook of Harm
Reduction International capture some of the central
issues being raised by the extremely high price of new
direct-acting antiviral drugs and call attention to what
this means for PWID in Europe.
• Slovenia’s exemplary national multidisciplinary
healthcare network for treating hepatitis C in people
who inject drugs is described by physician Mojca
Maticic, a hepatitis expert who has played a major role
in helping to develop the Slovenian model.
• Leon Wylie of Hepatitis Scotland and other key
actors involved in the Scottish Hepatitis C Action Plan
identify ways in which the acclaimed Scottish approach
can serve as a valuable example for others seeking to
develop effective national and pan-European responses
to hepatitis C.
• Astrid Leicht of Fixpunkt, a German nongovernmental
organisation working to promote the health of people who
use drugs, demonstrates the expertise that those working
at the community level are ready to contribute in “Improv-
ing the Quality of Needle and Syringe Programmes: an
Overlooked Strategy for Preventing Hepatitis C among
People Who Inject Drugs.”
• Ricardo Baptista Leite, a physician and Member of
Parliament in Portugal, explains the process that led to
the strategic consensus for the integrated management
of hepatitis C in Portugal and highlights primary
recommendations.
• Two contributions from Spain both look critically at
ECDC and EMCDDA Guidance: Prevention and Control
of Infectious Diseases among People Who Inject Drugs
[8]. Antonio Corbacho and co-authors representing five
Spanish drug user organisations share insights about
what this landmark guidance document means for their
constituencies, as well as identifying shortcomings and
proposing addenda that reflect drug users’ concerns. In
a similar vein but from a quite different vantage point,
Joan Colom i Farran of the Public Health Agency of
Catalonia offers a policy-maker’s perspective on ECDC
and EMCDDA Guidance, and in doing so draws out ele-
ments of the guidance that warrant more careful
consideration.
The publication also contains five research articles and
a discussion article that collectively demonstrate the
potential for smart research to help transform the politi-
cal and public health response to hepatitis C in Europe.
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Robert Heimer and colleagues present findings from a
bio-behavioural study on hepatitis C among PWID in
eight Russian cities, calling attention to the advanced
epidemic there. In “HIV and hepatitis C Co-infection in
Europe, Israel and Argentina: a EuroSIDA Perspective,”
Lars Peters and colleagues examine the nested hepatitis
cohort in one of the world’s major HIV cohorts. Mojca
Maticic and colleagues present findings that will be
valuable to advocates and policy-makers in their article,
“Are There National Strategies, Plans and Guidelines for
the Treatment of Hepatitis C in People who Inject
Drugs? A Survey of 33 European Countries.”
Alexander Spina and colleagues focus on the PWID
findings from the aforementioned first WHO global hepa-
titis policy report in “Policy Responses to Viral Hepatitis B
and C among People Who Inject Drugs in Member States
of the WHO European Region: a Sub-analysis of the
WHO 2013 Global Hepatitis Policy Survey.” Jeffrey V.
Lazarus and colleagues report worrisome findings about
low treatment levels in “A Systematic Review of Hepatitis
C Virus Treatment Uptake among People Who Inject
Drugs in the European Region,” while Amber Arain and
colleagues provide recommendations regarding hepatitis C
prevention, screening and treatment in prisons, a highly
neglected setting.
Finally, the supplement presents a timely roundtable
discussion entitled “How Lessons Learned from HIV
can Inform the Global Response to Viral Hepatitis” with
patient, physician, epidemiologist, qualitative researcher
and grassroots advocate perspectives.
What the editors find most striking about this unique
collection of pieces is that it embodies an incredible wealth
of knowledge drawn from important front-line work.
When we say this, we are referring to all of the front lines
that are so important in addressing the hepatitis C
epidemic in PWID communities. Many contributors to
this supplement are speaking on the basis of their own
direct experience grappling with enormous challenges – as
people who use or formerly used drugs, as people who
provide health care, addiction treatment, social support
and peer support to drug users, as researchers looking for
innovative ways to acquire evidence about an often-
inaccessible population, and as activists, advocates and
policy-makers who are fighting to wake up others regard-
ing the threat posed by hepatitis C and the moral impera-
tive to respond without judging anyone who is at risk.
Furthermore, many contributors transcend what might
be thought of as their proscribed roles as activists,
researchers, physicians, policy-makers and so on. We
hope that this approach is reflective of what is happen-
ing in the overall European response to hepatitis and
PWID, because it is exactly what is needed: physicians
must engage in policy issues, activists must persuade
others to support the most appropriate strategies and
interventions by using the dispassionate logic that is
characteristic of researchers, and public health adminis-
trators must inspire change by displaying the passion of
activists.
Pragmatism emerges as an important theme of the sup-
plement. For example, as much as good evidence is
required to inform the response to hepatitis C in Europe,
Joan Colom i Farran reminds readers of why it can also be
pragmatic to move forward on merely the basis of good
common sense. The author calls for supervised injecting
facilities to be emphasised much more in any future
edition of the ECDC and EMCDDA Guidance, noting:
I am aware that research on those facilities is lim-
ited, but do you really need much research to
prove that injecting inside these facilities is much
safer than injecting elsewhere? It is like needing to
prove that jumping from a plane with a parachute
is safer than jumping without one, is it not?
As this observation reminds us, a key to navigating so
many strategic considerations relating to hepatitis preven-
tion and treatment for PWID is knowing when more evi-
dence is needed and when it is time to act on the limited
available evidence in the interest of trying to save as many
lives as possible. As all types of stakeholders grapple with
this issue in the years to come, we hope that cues will be
taken from the invaluable insights of the most at-risk and
most affected communities. In that spirit, we would like to
conclude by quoting from the commentary provided by
the Spanish drug user organisations:
It would be difficult to find another at risk-popula-
tion whose needs have been so widely ignored. ….
Give us voice and respect, more often and in more
situations, and we are sure that this will make a
difference in the prevention of drug-related harm,
including harm from the transmission of hepatitis
C and other bloodborne viruses.
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